The estimated Net Worth of D Joseph Gersuk is at least 294 千$ dollars as of 6 September 2011. D Gersuk owns over 3,000 units of Angiodynamic Inc stock worth over 293,973$ and over the last 18 years D sold ANGO stock worth over 0$.
D has made over 1 trades of the Angiodynamic Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently D exercised 3,000 units of ANGO stock worth 40,470$ on 6 September 2011.
The largest trade D's ever made was exercising 3,000 units of Angiodynamic Inc stock on 6 September 2011 worth over 40,470$. On average, D trades about 231 units every 0 days since 2007. As of 6 September 2011 D still owns at least 39,619 units of Angiodynamic Inc stock.
You can see the complete history of D Gersuk stock trades at the bottom of the page.
D's mailing address filed with the SEC is 603 QUEENSBURY AVE., , QUEENSBURY, NY, 12804.
Over the last 20 years, insiders at Angiodynamic Inc have traded over 207,843,757$ worth of Angiodynamic Inc stock and bought 255,612 units worth 3,086,102$ . The most active insiders traders include David F Burgstahler、Sriram Venkataraman、Capital Partners Gp, Llc Av.... On average, Angiodynamic Inc executives and independent directors trade stock every 36 days with the average trade being worth of 826,492$. The most recent stock trade was executed by Laura Piccinini on 17 July 2024, trading 4,439 units of ANGO stock currently worth 32,937$.
founded in 1988 in queensbury, n.y., u.s., angiodynamics is today a nasdaq-listed public company. we are a leading provider of innovative medical devices used by interventional radiologists, nephrologists and surgeons for the minimally invasive treatment of cancer and peripheral vascular disease. our diverse product line includes market-leading radiofrequency ablation and nanoknife® systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. angiodynamics has distinguished itself as a dynamic brand in a technologically competitive, high-growth industry, through the company’s consistent ability to successfully develop and bring to market new technologies and products. angiodynamics believes it is well poised to continue that trend. looking into the future, the company plans to bring forth a continuing stream of innovations that greatly improve patie
Angiodynamic Inc executives and other stock owners filed with the SEC include: